Navigation Links
Ethnic Bridging in Phase 1 Clinical Trials: A Strategy for Enhancing Asset Value and Accelerating Global Drug Development, New Webinar Hosted by Xtalks
Date:1/20/2019

The possibility that ethnic differences exist in different populations with regards to drug metabolism and distribution has been documented for many years. These observed differences may be manifest in alterations in safety, efficacy and/or labeled dosages, or in terms of adverse event profiles in patients residing in different geographic regions. This created the perceived necessity to fully and separately develop new medicines for each geographic market.

This development practice evolved into a trend such that drug development was initiated in the USA or Europe, and development in other geographic regions followed in such countries as Japan, South Korea and Taiwan. Development in Canada, Australia, New Zealand, South Africa and South America generally kept pace with development in the USA and Europe. Consequently, throughout the 1980s and early 1990s there was an acknowledged 7 to 10 year ‘drug approval lag’ in Japan, South Korea and Taiwan. Thus, these populations suffered delayed access to new therapies even though safety and efficacy had already been established in other regions of the world. Consequently, it was difficult to explain to the patients residing in these regions why they had to wait so many years beyond the rest of the world to get access to these medications.

The urgent need to rationalize and harmonize regulations was understood by regulators worldwide, as well as the global pharmaceutical industry. As a result, ICH E5 – Ethnic Factors in the Acceptability of Foreign Clinical Data (5 Feb 1998) was published and the concept of global clinical development was widely and rapidly adopted.

Join Dr. Melton Affrime, PharmD, President and Chief Scientific Officer at WCCT Global in a live webinar on Tuesday, February 5, 2019 at 2pm EST to hear about:

  •     Specific case studies where ethnic bridging has been used in early clinical development
  •     Strategies on how to include ethnic bridging in your early clinical development plans
  •     How ethnic bridging can hasten regulatory acceptance of data worldwide

For more information or to register for this event, visit Ethnic Bridging in Phase 1 Clinical Trials: A Strategy for Enhancing Asset Value and Accelerating Global Drug.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Read the full story at https://www.prweb.com/releases/ethnic_bridging_in_phase_1_clinical_trials_a_strategy_for_enhancing_asset_value_and_accelerating_global_drug_development_new_webinar_hosted_by_xtalks/prweb16039983.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Scientists discover ethnic differences in immune response to TB bacterium
2. HIV medications dialogue differs by race, ethnicity
3. Parental disapproval contributes to racial/ethnic differences in prescription drug misuse by teens
4. Fathers ethnic background influences birthweight, study finds
5. Analysis of the Chinese facial profile: Contours of the side face in the Tu & Zang ethnic minorities
6. Racial and ethnic stereotypes may contribute to obesity among minorities
7. Race and ethnicity important when evaluating risk of fat around the heart
8. Penn study finds genetic mutations linked with ethnic disparities in cancer
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. Carnegie Mellon neuroscientists discover new phase of synaptic development
11. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2019)... CREEK, Calif. (PRWEB) , ... April 18, 2019 ... ... for the healthcare industry, today announced the launch of mSource® AI Contract Text ... extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased services spend ...
(Date:4/16/2019)... ... April 16, 2019 , ... HealthLink ... opening of its new medical device facility on Friday, April 12. Headquartered in ... TN the new facility includes 108,500 square feet and houses 32 employees enabling ...
(Date:4/16/2019)... ... April 16, 2019 , ... The International Society ... The 2019 ISPE Biopharmaceutical Manufacturing Conference , on 18–20 June and The ... one of the most influential bio hubs, Boston, Massachusetts USA, these concurrent events ...
Breaking Biology News(10 mins):
(Date:3/27/2019)... , ... March 27, 2019 , ... Lachman is sponsoring ... the Clayton Hotel Burlington Road, Dublin, Ireland. The executive team on site will be ... 4.0, two key tracks on the agenda this year. , Executives from Lachman participating ...
(Date:3/19/2019)... POWAY, Calif. (PRWEB) , ... March 19, 2019 , ... Bogey was nine years old ... advanced arthritis in his left hip. These ailments caused Bogey to experience problems with ... into vehicles, up stairs, and onto his special spot on the couch. , His owners, ...
(Date:3/18/2019)... ... March 18, 2019 , ... For more than 15 ... develop solutions that allow life science companies to easily comply with FDA 21 CFR ... Assurance ™ is a managed service delivering end-to-end GxP compliance from vendor audit through ...
(Date:3/14/2019)... ... March 14, 2019 , ... ON NOVEMBER 27, ... partner, the Eye Machine Canada Inc., had been given approval to begin a ... Age-Related Macular Degeneration (AMD). , The previous month, the medical devices bureau of ...
Breaking Biology Technology: